Johnson & Johnson is facing lawsuits, patent cliffs, and disruptive drug pricing negotiations. Despite that, the company's ...

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

Johnson & Johnson failed for years to resolve its talc liabilities in chapter 11, but is now gaining ground outside of ...

Johnson & Johnson has crushed the market over the past year. The healthcare giant faces some challenges that could harm its results. However, Johnson & Johnson's business looks strong enough to ...

A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the ...

Johnson & Johnson on Wednesday announced plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be ...

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

Royalty Pharma has inked a $500 million research-and-development co-funding agreement with Johnson & Johnson to support development of a proposed drug for autoimmune diseases.

Johnson & Johnson (NYSE: JNJ) on Monday reportedly secured a partial legal victory after Delaware's highest court overturned a portion of a $1 billion damages award tied to its acquisition of surgical ...

Johnson & Johnson (JNJ) is rated a Hold: defensive quality, DCF valuation, easing litigation, and dividend outlook—see key ...

Bayer BAYGn.DE sued Johnson & Johnson JNJ.N on Monday, accusing the drugmaker of falsely advertising a rival multibillion-dollar drug to treat prostate cancer. In a complaint filed in Manhattan ...